{
  "docId": "019de073-742c-704c-a810-4500da4f1d81",
  "docSlug": "e78883ddf681fdb15564423388c7a078",
  "documentTitle": "Allarity Therapeutics | Investor Conference Presentation Deck | 23 slides",
  "authorId": "allarity-therapeutics",
  "authorName": "Allarity Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 23,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide demonstrates the predictive power of the DRP biomarker by contrasting the entire study population (no benefit) with the DRP-selected subgroup (significant benefit).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-742c-704c-a810-4500da4f1d81/10",
  "deckHref": "/decks/019de073-742c-704c-a810-4500da4f1d81",
  "deckJsonHref": "/decks/019de073-742c-704c-a810-4500da4f1d81.json",
  "deckAnchorHref": "/decks/019de073-742c-704c-a810-4500da4f1d81#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.35,
        "x": 0.38,
        "y": 0.25
      },
      "kind": "chart",
      "text": "DRP selects survivors in dovitinib arm but not in sorafenib arm",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d4240f9-eae3-4a81-b79c-cdf236b719fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Kaplan-Meier Plot - Overall Survival -Entire arms",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d638428a-5ebf-4689-a70f-ff08c65fcc40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.75,
        "y": 0.25
      },
      "kind": "list",
      "text": "Dovitinib-DRP® positive: median 15.0 mo. OS (95%CI 12.9-26.3); Dovitinib-DRP® negative: median 9.1 mo. OS (95% CI 7.6-13,2); Hazard Ratio: 0.60 (95% CI 0.39-0.91); Dovitinib-DRP® does not select Sorafenib responders",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40f5c8d9-3818-4a65-9aac-06298a77f139",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. NCT01223027; 49 out of 135 patients that consented to give biopsy that passed QC were DRP positive (36%). If samples are macrodissected to remove necrosis the median increases to 24.2 mo in the Dovitinib-DRP positive arm.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f47712a2-ff9b-471e-b9a9-d408c7a30832",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "Dovitinib-DRP® (58 mRNAs) Identified Patients with Overall Survival (OS) Benefit in Novartis Phase 3 in 3rd line RCC",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2c857df-7a13-4363-ab59-91fbac91d110",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Our Validated Dovitinib-DRP® Identifies Responsive Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3448b84f-db13-47bf-b132-4b408d248ab6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "68fe3a90-0b83-4901-862c-2e1279bd6108",
      "evidence": "The slide presents a comparison of patient outcomes with and without Dovitinib-DRP, highlighting improved overall survival for patients with high DRP scores.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "14908850-fc0f-4800-bf9e-253e00ff8676",
      "evidence": "Contrasts the 'entire arm' (before/baseline) with the 'DRP positive' (after/intervention) to show efficacy.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 5,
      "beatId": "e820002d-ccbd-4705-8e3b-e07f363c4b30",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation agitates the problem by highlighting the limitations of current cancer treatments and the potential benefits of DRP.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    },
    {
      "to": 23,
      "from": 10,
      "beatId": "b256bbaf-5ead-4fee-9327-1e3695ac93a7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation presents DRP as a solution to the problem, highlighting its potential to personalize cancer care and improve patient outcomes.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "44643853-e437-4ad1-bf89-99af043fe3be",
      "evidence": "The presentation uses before-after loops to show the potential benefits of DRP in predicting patient response to therapy.",
      "position": 0,
      "objective": "To show the benefits of using DRP for personalized cancer care",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}